Skip to main content

NICE TAs

11/10/2021
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
11/10/2021
TA723: Bimekizumab for treating moderate to severe plaque psoriasis
11/10/2021
TA721: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
11/10/2021
TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
11/10/2021
TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
11/10/2021
TA728: Midostaurin for treating advanced systemic mastocytosis
11/10/2021
TA729: Sapropterin for treating hyperphenylalaninaemia in phenylketonuria
11/10/2021
TA730: Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)
11/10/2021
TA731: Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)
11/10/2021
TA732: Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)
11/10/2021
TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people
16/12/2020
TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
25/11/2020
TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
25/11/2020
TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
18/11/2020
TA656: Siponimod for treating secondary progressive multiple sclerosis
18/11/2020
TA657: Carfilzomib for previously treated multiple myeloma
18/11/2020
TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
18/11/2020
TA659: Galcanezumab for preventing migraine
21/10/2020
TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
20/10/2020
TA457: Carfilzomib for previously treated multiple myeloma

Evidence-based recommendations on carfilzomib (Kyprolis) for treating multiple myeloma in adults.

Follow AWTTC: